Clark SD, Abi-Dargham A. The role of dynorphin and the kappa opioid receptor in the symptomatology of schizophrenia: a review of the evidence. Biol Psychiatry. 2019;86:502–11.

Article  PubMed  CAS  Google Scholar 

Clark SD, et al. Opioid antagonists are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of controlled trials. Neuropsychopharmacology. 2020;45:1860–9.

Article  PubMed  PubMed Central  Google Scholar 

Watson SJ, et al. Effects of naloxone on schizophrenia: reduction in hallucinations in a subpopulation of subjects. Science. 1978;201:73–6.

Article  PubMed  CAS  Google Scholar 

Emrich HM, et al. Indication of an antipsychotic action of the opiate antagonist naloxone. Pharmakopsychiatr Neuropsychopharmakol. 1977;10:265–70.

Article  PubMed  CAS  Google Scholar 

Berger PA, et al. The effects of naloxone in chronic schizophrenia. Am J Psychiatry. 1981;138:913–8.

Article  PubMed  CAS  Google Scholar 

Di Chiara G, Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharm Exp Ther. 1988;244:1067–80.

Google Scholar 

Britt JP, McGehee DS. Presynaptic opioid and nicotinic receptor modulation of dopamine overflow in the nucleus accumbens. J Neurosci. 2008;28:1672–81.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Howes OD, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry. 2012;69:776–86.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull. 2009;35:549–62.

Article  PubMed  PubMed Central  Google Scholar 

Laruelle M, ABi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J Psychopharmacol. 1999;13:358–78.

Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science. 1997;275:1593–9. p.

Article  PubMed  CAS  Google Scholar 

Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev. 1998;28:309–69.

Article  PubMed  CAS  Google Scholar 

Kegeles L, et al. Increased synaptic dopamine in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry. 2010;67:231–9.

Article  PubMed  CAS  Google Scholar 

Slifstein M, et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry. 2015;72:316–24.

Article  PubMed  PubMed Central  Google Scholar 

Naganawa M, et al. Evaluation of F-18-LY2459989 for imaging the kappa opioid receptor in humans. J Nucl Med. 2019;60:577.

Nabulsi NB, et al. Evaluation of the first F-18-labeled PET radiotracer F-18-LY2459989 for imaging kappa opioid receptor in humans. J Cereb Blood Flow Metab. 2019;39:89–89.

Google Scholar 

Cassidy CM, et al. Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. Proc Natl Acad Sci USA. 2019;116:5108–17.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome scale (PANSS) for schizophrenia. Schiz Bull. 1987;13:261–76.

Article  CAS  Google Scholar 

Andreasen, NC. Scale for the assessment of negative symptoms/scale for the assessment of positive symptoms. Iowa City: University of Iowa Press; 1984.

Cai Z, et al. Fluorine-18-labeled antagonist for PET imaging of kappa opioid receptors. ACS Chem Neurosci. 2017;8:12–16.

Article  PubMed  CAS  Google Scholar 

Mawlawi O, et al. Performance characteristics of a head immobilization device for PET imaging. J Nucl Med. 1999;40:281P–281P.

Google Scholar 

Abi-Dargham A, et al. Increased prefrontal cortical D(1) receptors in drug naive patients with schizophrenia: a PET study with [(1)(1)C]NNC112. J Psychopharmacol. 2012;26:794–805.

Article  PubMed  Google Scholar 

SPM Online Documentation 2021. https://www.fil.ion.ucl.ac.uk/spm/doc/manual.pdf.

Chen X, et al. Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach. Magn Reson Imaging. 2014;32:1301–6.

Article  PubMed  Google Scholar 

Wengler K, et al. Reproducibility assessment of neuromelanin-sensitive magnetic resonance imaging protocols for region-of-interest and voxelwise analyses. Neuroimage. 2020;208:116457.

Article  PubMed  CAS  Google Scholar 

Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull. 2006;32:238–45.

Article  PubMed  Google Scholar 

Ueno F, et al. Neuromelanin accumulation in patients with schizophrenia: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2022;132:1205–13.

Article  PubMed  CAS  Google Scholar 

O’Brien CP, et al. Endogenous opioids in cerebrospinal fluid of opioid-dependent humans. Biol Psychiatry. 1988;24:649–62.

Article  PubMed  Google Scholar 

Shahkarami K, et al. Evaluation of dynorphin and kappa-opioid receptor level in the human blood lymphocytes and plasma: Possible role as a biomarker in severe opioid use disorder. Drug Alcohol Depend. 2019;205:107638.

Article  PubMed  CAS  Google Scholar 

Wengler K, et al. Generalizability and out-of-sample predictive ability of associations between neuromelanin-sensitive magnetic resonance imaging and psychosis in antipsychotic-free individuals. JAMA Psychiatry. 2024;81:198–208.

Article  PubMed  Google Scholar 

Krystal AD, et al. A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating kappa-opioid antagonism as a treatment for anhedonia. Nat Med. 2020;26:760–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schmidt ME, et al. Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study. Neuropsychopharmacology. 2024;49:1437–47.

Harvey PO, et al. Functional neural substrates of self-reported physical anhedonia in non-clinical individuals and in patients with schizophrenia. J Psychiatr Res. 2010;44:707–16.

Article  PubMed  Google Scholar 

Treadway MT, Zald DH. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev. 2011;35:537–55.

Article  PubMed  Google Scholar 

First M, et al., Structured clinical interview for DSM-IV Axis I Disorders (SCID-I/P, Version 2.0). New York: Biometrics Research Dept., New York State Psychiatric Institute; 1995.

First M, et al., Structured clinical interview for DSM-5-research version (SCID-5 for DSM-5, research version, SCID-5-RV), ed. a.p. association. Arlington, VA; 2015.

Skumlien M, et al. The acute and non-acute effects of cannabis on reward processing: A systematic review. Neurosci Biobehav Rev. 2021;130:512–28.

Article  PubMed  CAS  Google Scholar 

Volkow ND, et al. Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. Proc Natl Acad Sci USA. 2014;111:E3149–56.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Abplanalp SJ, et al. Understanding connections and boundaries between positive symptoms, negative symptoms, and role functioning among individuals with schizophrenia: a network psychometric approach. JAMA Psychiatry. 2022;79:1014–22.

Article  PubMed  PubMed Central